Xenon (XENE) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Xenon Pharmaceuticals has unveiled promising long-term data from its X-TOLE study, showing that its drug azetukalner significantly reduces seizure frequency in patients with focal onset seizures. Impressively, one-third of those treated for over three years achieved complete seizure freedom, highlighting the drug’s potential to improve epilepsy treatment.
For further insights into XENE stock, check out TipRanks’ Stock Analysis page.
